EASL publishes online recommendations on the management of hepatitis C

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress (ILC). These EASL recommendations reflect the approval of three new direct-acting antivirals (DAAs) during 2014 by the European Medicines Agency.

It is estimated that approximately 185 million people are infected with HCV on a global scale, with approximately 150 million people living with chronic infection. In Europe, between 7.3 million and 8.8 million people are infected with HCV and approximately 3-4 million people become newly infected each year.

Three new HCV DAAs that are more efficacious and better-tolerated, will be on the European market in the first half of 2014, for use as part of combination therapies for HCV infection. Sofosbuvir, a nucleotide analogue inhibitor of HCV ribonucleic acid (RNA)-dependent RNA polymerase, was approved in January 2014. Simeprevir, a second-wave, first-generation NS3/4A protease inhibitor will be approved in May 2014. Daclatasvir, an NS5A inhibitor, is likely to be approved in August or September 2014.

Coordinator of the recommendations and Director of the French National Reference Centre for Viral Hepatitis Professor Jean-Michel Pawlotsky said: "Since EASL published the HCV Clinical Practice Guidelines in 2013, the paradigm for HCV has changed with three additional direct-acting antivirals - sofosbuvir, simeprevir and daclatasvir –scheduled for approval this year for use in patients infected with HCV genotype 1."

"These groundbreaking drugs continue to revolutionise treatment for HCV patients, including those who failed to respond to previous therapies. The new on-line recommendations provide essential information on the recommended use of these new compounds with and without interferon to help prescribers deliver optimal care for their HCV patients."

Based on a systematic review of existing literature, the new recommendations provide best practice on a number of key areas:

  • Indications for treatment: who should be treated?
  • Available drugs (approved by EMA before the end of 2014)
  • Treatment of chronic hepatitis C
  • Treatment monitoring
  • Measures to improve treatment adherence
  • Post-treatment follow-up of patients who achieve an SVR
  • Retreatment of non-sustained virological responders
  • Treatment of patients with severe liver disease
  • Treatment of special groups

Commenting on the new on-line recommendations, EASL Governing Board member and recommendation panel member Dr. Alessio Aghemo said: "These new EASL on-line recommendations on the management of HCV reflect how the treatment landscape has evolved for this disease, and will further help physicians and other healthcare providers optimise management of with acute and chronic HCV."

The new EASL on-line HCV management will be presented during a session at the ILCTM in London on Saturday 12th April 2014 from 14:00 to 15:00.

Related Stories

Study quantifies prevalence of chronic HCV infection

date Mar 04, 2014

(HealthDay)—The prevalence of hepatitis C virus (HCV) infection is about 1 percent, with 2.7 million U.S. residents estimated as having chronic HCV infection, according to a study published in the March ...

Recommended for you

Endoscopes linked to outbreak of drug-resistant E. coli

date 9 minutes ago

An outbreak of a novel Escherichia coli (E. coli) strain resistant to antibiotics has been linked to contaminated endoscopes in a Washington state hospital. The study indicates that industry standard clea ...

Fighting back against superbugs

date 2 hours ago

Antibiotics—and antibiotic resistance—are in the news once again, with announcements by McDonald's and Costco that they will eliminate antibiotics that are important to human medicine from use in the ...

Harnessing the power of microbes as therapeutics

date 3 hours ago

A new report recently released by the American Academy of Microbiology discusses how specific microbes can be modified to enhance their therapeutic potential for treating human diseases such as cancer and antibiotic resistant ...

New genetic link found for alcohol-related liver cirrhosis

date 3 hours ago

In most people, any liver damage that might occur from drinking alcohol is reversible. However, in 25 to 30 percent of alcoholics what begins as accumulation of fat in the liver progresses to inflammation, fibrosis and ultimately ...

Could camel antibodies protect humans from MERS?

date 3 hours ago

Antibodies from dromedary camels protected uninfected mice from Middle East Respiratory Syndrome (MERS), and helped infected mice expunge the disease, according to a study published online March 18th in the ...

Sierra Leone ends anti-Ebola lockdown after three days

date 7 hours ago

Sierra Leoneans were once again allowed to leave their homes Sunday evening after the government announced the end of a three-day nationwide lockdown aimed at preventing a resurgence of the deadly Ebola virus.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.